Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
Public Policy
Share |

Throughout 2016, Life Science Washington will focus on smaller, personal engagements with legislators and policy makers.

This approach will include several key elements such as roundtable discussions with policy makers and direct conversations with legislators. Often, these discussions will be paired with a facility tour, which gives policy makers a chance to better understand the incredible work our members are doing to impact people’s lives. During the legislative session, we will focus on facilitating personal conversations between industry executives and legislators at key times during the session.

To help us implement this more personal approach, please send us an email if you have a personal relationship with a member of the legislature so that we can include you in those conversations. Likewise, if you or your company would like to host a roundtable discussion at your facility, please let us know and we will get in touch with you to coordinate the details. Life Science Washington will handle everything! You just need to do what you do best — show how your company is developing products that improve people’s lives!


If you would like to be part of this year’s engagement strategy, please email Marc Cummings, your VP of Public Policy & External Affairs at marc@washbio.org

 


Drug Pricing is in the News; Here's What You Should Know

 

Recently, news and political discourse about the healthcare and pharmaceutical industry has been dominated by discussions about the cost of drugs.  As we enter a Presidential election year, it is likely that drug costs and pricing will continue to be front and center.  While Life Science Washington members are more likely to be pre-revenue companies in the process of developing innovative cures and therapies, rather than actively selling a FDA-approved drug, the debate about drug pricing has the potential to dramatically impact the investment environment and availability of private capital for all biotechnology companies and research organizations.

To address this issue, the Biotechnology Industry Association (BIO) recently drafted a white paper designed to help people better understand the innovative work we do and the risk that is undertaken to bring life-saving cures and innovative therapies to market.

 

If you are interested in receiving the full white paper titled, “Unleashing the Next Generation of Biotechnology Innovation,” please email marc.cummings@washbio.orgLikewise, if you have comments or feedback please let us know.

more Calendar

6/1/2016 » 6/2/2016
2016 Life Science Innovation Northwest (LSINW)

7/27/2016
Leadership EDGE for WOMEN

Featured Partners
BioTech Primer Inc.BioTech Primer develops and delivers customized training to the Life Sciences community

Membership Management Software Powered by YourMembership.com®  ::  Legal